Amedeo Smart

Free Medical Literature Service

 

Amedeo

Diabetes
  Free Subscription

Articles published in
Kidney Int
    July 2024
  1. DRUEKE TB, Massy ZA
    Unexpected metabolic effects of sodium-glucose cotransporter 2 inhibitors.
    Kidney Int. 2024;106:12-15.
    >> Share

  2. FENG Y, Sun Z, Fu J, Zhong F, et al
    Podocyte-derived soluble RARRES1 drives kidney disease progression through direct podocyte and proximal tubular injury.
    Kidney Int. 2024;106:50-66.
    >> Share

    June 2024
  3. NANGAKU M
    SGLT2 inhibitor: 2-way superstar in nephrology?
    Kidney Int. 2024;105:1176-1177.
    >> Share

  4. KUME S, Packer M
    SGLT2 inhibitors act as metabolic transducers to restore healthy nutrient deprivation and surplus signaling in the kidney.
    Kidney Int. 2024;105:1172-1176.
    >> Share

  5. YAU K, Cherney DZI, van Raalte DH, Wever BE, et al
    Kidney protective mechanisms of SGLT2 inhibitors: evidence for a hemodynamic effect.
    Kidney Int. 2024;105:1168-1172.
    >> Share

  6. MCEVOY CM, Yuen DA
    Not too much, not too little-just the right amount: the story of YAP in the podocyte.
    Kidney Int. 2024;105:1157-1159.
    >> Share

    May 2024
  7. WADA Y, Kidokoro K, Kondo M, Tokuyama A, et al
    Evaluation of glomerular hemodynamic changes by sodium-glucose-transporter 2 inhibition in type 2 diabetic rats using in vivo imaging.
    Kidney Int. 2024 May 25:S0085-2538(24)00340-5. doi: 10.1016/j.kint.2024.
    >> Share

  8. HONG YA, Nangaku M
    Endogenous adenine as a key player in diabetic kidney disease progression: an integrated multiomics approach.
    Kidney Int. 2024;105:918-920.
    >> Share

  9. WANG L, Tian H, Wang H, Mao X, et al
    Disrupting circadian control of autophagy induces podocyte injury and proteinuria.
    Kidney Int. 2024;105:1020-1034.
    >> Share

    April 2024
  10. MURPHY DP, Wolfson J, Reule S, Johansen KL, et al
    A cohort study of sodium-glucose cotransporter-2 inhibitors after acute kidney injury among Veterans with diabetic kidney disease.
    Kidney Int. 2024 Apr 27:S0085-2538(24)00309-0. doi: 10.1016/j.kint.2024.
    >> Share

    March 2024
  11. NEGRI AL
    Sodium-glucose cotransporter 2 inhibitors in the treatment of refractory hypomagnesemia.
    Kidney Int. 2024;105:638.
    >> Share

  12. SHAH CV
    Sodium-glucose cotransporter 2 inhibition, epidermal growth factor, and magnesium homeostasis: is there a link?
    Kidney Int. 2024;105:638-639.
    >> Share

  13. CHEN JJ, Lee TH, Yang HY
    Exploring nontraditional cardiorenal advantages of SGLT-2 inhibitors and GLP-1 receptor agonists.
    Kidney Int. 2024;105:442-444.
    >> Share

    February 2024
  14. CHEN J, Wang X, He Q, Yang HC, et al
    Inhibition of transcriptional coactivator YAP Impairs the expression and function of transcription factor WT1 in diabetic podocyte injury.
    Kidney Int. 2024 Feb 27:S0085-2538(24)00160-1. doi: 10.1016/j.kint.2024.
    >> Share

    January 2024
  15. MUTO Y, Humphreys BD
    Leveraging multimodal chromatin profiling to identify a new potential driver of diabetic kidney disease.
    Kidney Int. 2024;105:25-27.
    >> Share

    December 2023
  16. FU EL, Mastrorilli J, Bykov K, Wexler DJ, et al
    A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.
    Kidney Int. 2023 Dec 13:S0085-2538(23)00865-7. doi: 10.1016/j.kint.2023.
    >> Share

  17. SOURRIS KC, Ding Y, Maxwell SS, Al-Sharea A, et al
    Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation.
    Kidney Int. 2023 Dec 5:S0085-2538(23)00756-1. doi: 10.1016/j.kint.2023.
    >> Share

  18. LIZOTTE F, Rousseau M, Denhez B, Levesque D, et al
    Erratum to "Deletion of protein tyrosine phosphatase SHP-1 restores SUMOylation of podocin and reverses the progression of diabetic kidney disease." Kidney Int. 2023;104:787-802.
    Kidney Int. 2023;104:1228.
    >> Share

  19. IWAGAMI M
    Post hoc analysis of the SONAR trial: potential analgesic effects of atrasentan?
    Kidney Int. 2023;104:1062-1064.
    >> Share

    November 2023
  20. EUN M, Kim D, Shin SI, Yang HO, et al
    Chromatin accessibility analysis and architectural profiling of human kidneys reveal key cell types and a regulator of diabetic kidney disease.
    Kidney Int. 2023 Nov 2:S0085-2538(23)00757-3. doi: 10.1016/j.kint.2023.
    >> Share

  21. FANG Z, Lee K, He JC
    A central role for mesangial cells in the initiation of diabetic nephropathy.
    Kidney Int. 2023;104:872-874.
    >> Share

    October 2023
  22. AZUSHIMA K, Kovalik JP, Yamaji T, Ching J, et al
    Abnormal lactate metabolism is linked to albuminuria and kidney injury in diabetic nephropathy.
    Kidney Int. 2023 Oct 5:S0085-2538(23)00565-3. doi: 10.1016/j.kint.2023.
    >> Share

    September 2023
  23. SMERKOUS D, Mauer M, Tondel C, Svarstad E, et al
    Development of an automated estimation of foot process width using deep learning in kidney biopsies from patients with Fabry, minimal change, and diabetic kidney diseases.
    Kidney Int. 2023 Sep 27:S0085-2538(23)00675-0. doi: 10.1016/j.kint.2023.
    >> Share

    August 2023
  24. CHAN KW, Smeijer JD, Schechter M, Jongs N, et al
    Post-hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.
    Kidney Int. 2023 Aug 30:S0085-2538(23)00610-5. doi: 10.1016/j.kint.2023.
    >> Share

  25. SEN T, Ju W, Nair V, Ladd P, et al
    Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes.
    Kidney Int. 2023 Aug 3:S0085-2538(23)00537-9. doi: 10.1016/j.kint.2023.
    >> Share

    July 2023
  26. LIZOTTE F, Rousseau M, Denhez B, Levesque D, et al
    Deletion of protein tyrosine phosphatase SHP-1 restores SUMOylation of podocin and reverses the progression of diabetic kidney disease.
    Kidney Int. 2023 Jul 26:S0085-2538(23)00502-1. doi: 10.1016/j.kint.2023.
    >> Share

  27. HONG S, Kim KS, Han K, Park CY, et al
    A cohort study found a high risk of end-stage kidney disease associated with acromegaly.
    Kidney Int. 2023 Jul 23:S0085-2538(23)00501-X. doi: 10.1016/j.kint.2023.
    >> Share

  28. MIMURA I, Nangaku M
    Epigenetic regulation of angiogenesis and ischemic response by long noncoding RNA LEENE in diabetes.
    Kidney Int. 2023 Jul 5:S0085-2538(23)00483-0. doi: 10.1016/j.kint.2023.
    >> Share

  29. HEERSPINK HJL, Jongs N, Neuen BL, Schloemer P, et al
    Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials.
    Kidney Int. 2023;104:181-188.
    >> Share

    April 2023
  30. CHAPMAN D, Judge PK, Sardell RJ, Staplin N, et al
    Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors.
    Kidney Int. 2023;103:787-790.
    >> Share

  31. CHEN Z, Zhu Z, Liang W, Luo Z, et al
    Reduction of anaerobic glycolysis contributes to angiotensin II-induced podocyte injury with foot process effacement.
    Kidney Int. 2023;103:735-748.
    >> Share

    February 2023
  32. TUTTLE KR, Bosch-Traberg H, Cherney DZI, Hadjadj S, et al
    Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared to placebo.
    Kidney Int. 2023 Feb 2:S0085-2538(23)00056-X. doi: 10.1016/j.kint.2022.
    >> Share

  33. CAZA TN, Larsen CP
    False-positive anti-PLA2R ELISA testing in patients with diabetes mellitus.
    Kidney Int. 2023;103:425.
    >> Share

    January 2023
  34. FU EL, Kutz A, Desai RJ
    Finerenone in chronic kidney disease and type 2 diabetes: the known and the unknown.
    Kidney Int. 2023;103:30-33.
    >> Share

    December 2022
  35. RAYEGO-MATEOS S, Rodrigues-Diez R, Fernandez-Fernandez B, Mora-Fernandez C, et al
    Targeting inflammation to treat diabetic kidney disease: the road to 2030.
    Kidney Int. 2022 Dec 2:S0085-2538(22)01017-1. doi: 10.1016/j.kint.2022.
    >> Share

  36. WU H, Humphreys BD
    Immune cell heterogeneity in a mouse model of diabetic kidney disease.
    Kidney Int. 2022;102:1215-1216.
    >> Share

    November 2022

  37. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.
    Kidney Int. 2022;102.
    >> Share

  38. ROSSING P, Caramori ML, Chan JCN, Heerspink HJL, et al
    Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence.
    Kidney Int. 2022;102:990-999.
    >> Share

    October 2022
  39. BAKRIS GL, Ruilope LM, Anker SD, Filippatos G, et al
    Analysis from the FIDELITY study examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.
    Kidney Int. 2022 Oct 28. pii: S0085-2538(22)00910.
    >> Share

  40. KRISHNAN S, Manoharan J, Wang H, Gupta D, et al
    CD248 induces a maladaptive unfolded protein response in diabetic kidney disease.
    Kidney Int. 2022 Oct 26. pii: S0085-2538(22)00904.
    >> Share

  41. LASSEN E, Bouchareb R, Daehn IS
    Podocyte as the link between sterile inflammation and diabetic kidney disease.
    Kidney Int. 2022;102:688-690.
    >> Share

    September 2022
  42. DE BOER IH, Khunti K, Sadusky T, Tuttle KR, et al
    Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).
    Kidney Int. 2022 Sep 27. pii: S0085-2538(22)00634.
    >> Share

  43. FU J, Sun Z, Wang X, Zhang T, et al
    The single-cell landscape of kidney immune cells reveals transcriptional heterogeneity in early diabetic kidney disease.
    Kidney Int. 2022 Sep 12. pii: S0085-2538(22)00715.
    >> Share

  44. SPEER T, Schunk SJ
    Klotho in diabetic kidney disease: more than dust in the Wnt.
    Kidney Int. 2022;102:469-471.
    >> Share

  45. ZHAN P, Zhang Y, Shi W, Liu X, et al
    Myeloid-derived growth factor deficiency exacerbates mitotic catastrophe of podocytes in glomerular disease.
    Kidney Int. 2022;102:546-559.
    >> Share

    August 2022
  46. STEFANSSON VTN, Nair V, Melsom T, Looker HC, et al
    Molecular Programs Associated with Glomerular Hyperfiltration in Early Diabetic Kidney Disease.
    Kidney Int. 2022 Aug 30. pii: S0085-2538(22)00689.
    >> Share

  47. XIA Y, Coates PT, Nangaku M
    How does diabetes cause susceptibility to COVID in the kidney: new clues provided by organoids.
    Kidney Int. 2022 Aug 10. pii: S0085-2538(22)00608.
    >> Share

  48. SUZUKI Y, Kaneko H, Okada A, Matsuoka S, et al
    Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium-glucose cotransporter-2 inhibitors.
    Kidney Int. 2022 Aug 4. pii: S0085-2538(22)00510.
    >> Share

  49. ZHANG J, Cai J, Cui Y, Jiang S, et al
    Corrigendum to Zhang J, Cai J, Cui Y, Jiang S, Wei J, Kim YC, Chan J, Thalakola A, Le T, Xu L, Wang L, Jiang K, Wang X, Wang H, Cheng F, Buggs J, Koepsell H, Vallon V, Liu R. "Role of the macula densa sodium glucose cotransporter type 1-neuronal nitri
    Kidney Int. 2022;102:448.
    >> Share

  50. RHEE EP
    Proteomic discovery in diabetic kidney disease-to what end?
    Kidney Int. 2022;102:236-238.
    >> Share

    July 2022
  51. ZENG W, Beyene HB, Kuokkanen M, Miao G, et al
    Lipidomic profiling in the Strong Heart Study identified American Indians at risk of chronic kidney disease.
    Kidney Int. 2022 Jul 16. pii: S0085-2538(22)00536.
    >> Share

  52. JAGANNATHAN G, Finkielstein VA, Markowitz GS, Kudose S, et al
    Armanni-Ebstein lesion in a diabetic patient with acute tubular injury.
    Kidney Int. 2022;102:213.
    >> Share

    June 2022
  53. SHAHZAD K, Fatima S, Khawaja H, Elwakiel A, et al
    Podocyte-specific Nlrp3 inflammasome activation promotes diabetic kidney disease.
    Kidney Int. 2022 Jun 29. pii: S0085-2538(22)00513.
    >> Share

  54. TUTTLE KR, Agarwal R, Alpers CE, Bakris GL, et al
    Molecular Mechanisms and Therapeutic Targets for Diabetic Kidney Disease.
    Kidney Int. 2022 Jun 2. pii: S0085-2538(22)00436.
    >> Share


  55. Corrigendum to Fang Y, Chen B, Gong AY, et al. "The ketone body beta-hydroxybutyrate mitigates the senescence response of glomerular podocytes to diabetic insults." Kidney Int. 2021;100:1037-1053.
    Kidney Int. 2022;101:1301-1302.
    >> Share

    May 2022
  56. CHEN X, Tan H, Xu J, Tian Y, et al
    Klotho-derived peptide 6 ameliorates diabetic kidney disease by targeting Wnt/beta-catenin signaling.
    Kidney Int. 2022 May 26. pii: S0085-2538(22)00378.
    >> Share

  57. MONTAGUD-MARRAHI E, Cuadrado-Payan E, Hermida E, Cacho J, et al
    Preemptive simultaneous pancreas kidney transplantation has survival benefit to patient.
    Kidney Int. 2022 May 26. pii: S0085-2538(22)00385.
    >> Share

  58. KOBAYASHI H, Looker HC, Satake E, Saulnier PJ, et al
    Results of untargeted analysis using the SOMAscan proteomics platform indicates novel associations of circulating proteins with risk of progression to kidney failure in diabetes.
    Kidney Int. 2022 May 23. pii: S0085-2538(22)00372.
    >> Share

  59. LI H, Zhao X, Zheng L, Wang X, et al
    Bruceine A protects against diabetic kidney disease via inhibiting galectin-1.
    Kidney Int. 2022 May 19. pii: S0085-2538(22)00369.
    >> Share

  60. NAGAI Y, Matoba K, Takeda Y, Yako H, et al
    Rho-associated, coiled-coil-containing protein kinase 1 regulates development of diabetic kidney disease via modulation of fatty acid metabolism.
    Kidney Int. 2022 May 18. pii: S0085-2538(22)00370.
    >> Share

  61. PRUIJM M, Phan O, Zanchi A
    Metformin versus SGLT-2 inhibitors: how low can we go?
    Kidney Int. 2022;101:874-877.
    >> Share

  62. NISHI H
    Lay A TRAP for myeloid cell response in diabetic kidney disease.
    Kidney Int. 2022;101:872-874.
    >> Share

    April 2022
  63. XIE Y, E J, Cai H, Zhong F, et al
    Reticulon-1A mediates diabetic kidney disease progression through endoplasmic reticulum-mitochondrial contacts in tubular epithelial cells.
    Kidney Int. 2022 Apr 22. pii: S0085-2538(22)00336.
    >> Share

    March 2022
  64. CORREMANS R, Neven E, Maudsley S, Leysen H, et al
    Progression of established non-diabetic chronic kidney disease is halted by metformin treatment in rats.
    Kidney Int. 2022 Mar 7. pii: S0085-2538(22)00176.
    >> Share

  65. PRESSLY JD, Ge M, Fornoni A
    LPCing through the nephron accelerates diabetic kidney disease.
    Kidney Int. 2022;101:454-456.
    >> Share

    February 2022
  66. HARUHARA K, Suzuki T, Wakui H, Azushima K, et al
    Deficiency of the kidney tubular angiotensin II type1 receptor-associated protein ATRAP exacerbates streptozotocin-induced diabetic glomerular injury via reducing protective macrophage polarization.
    Kidney Int. 2022 Feb 28. pii: S0085-2538(22)00161.
    >> Share

  67. SASAKO T, Yamauchi T
    Addressing screams for evidence on renoprotection by GLP-1 receptor agonists.
    Kidney Int. 2022;101:222-224.
    >> Share

  68. XU Y, Fu EL, Clase CM, Mazhar F, et al
    GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes.
    Kidney Int. 2022;101:360-368.
    >> Share

  69. HONG Q, Cai H, Zhang L, Li Z, et al
    Modulation of transforming growth factor-beta-induced kidney fibrosis by leucine-rich -2 glycoprotein-1.
    Kidney Int. 2022;101:299-314.
    >> Share

    January 2022
  70. HASEGAWA S, Nangaku M
    SGLT2 inhibition in chronic kidney disease: a preventive strategy against acute kidney injury at the same time?
    Kidney Int. 2022;101:20-22.
    >> Share

    December 2021

  71. Corrigendum to Mann JFE, Muskiet MHA. Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists. Kidney Int. 2021;99:314-318.
    Kidney Int. 2021;100:1351-1352.
    >> Share


  72. Corrigendum to Wu L, Liu C, Chang D-Y, et al. Annexin A1 alleviates kidney injury by promoting the resolution of inflammation in diabetic nephropathy. Kidney Int. 2021;100:107-121.
    Kidney Int. 2021;100:1349-1350.
    >> Share

    November 2021
  73. YOSHIOKA K, Hirakawa Y, Kurano M, Ube Y, et al
    Lysophosphatidylcholine mediates fast decline in kidney function in diabetic kidney disease.
    Kidney Int. 2021 Nov 29. pii: S0085-2538(21)01084.
    >> Share

  74. ZHANG J, Cai J, Cui Y, Jiang S, et al
    Role of the macula densa sodium glucose cotransporter type 1-nitric oxide synthase 1-tubuloglomerular feedback pathway in diabetic hyperfiltration.
    Kidney Int. 2021 Nov 26. pii: S0085-2538(21)01078.
    >> Share

  75. ANSERMET C, Centeno G, Bignon Y, Ortiz D, et al
    Dysfunction of the circadian clock in the kidney tubule leads to enhanced kidney gluconeogenesis and exacerbated hyperglycemia in diabetes.
    Kidney Int. 2021 Nov 24. pii: S0085-2538(21)01081.
    >> Share

  76. KAESLER N, Schreibing F, Speer T, Puente-Secades S, et al
    Altered vitamin K biodistribution and metabolism in experimental and human chronic kidney disease.
    Kidney Int. 2021 Nov 10. pii: S0085-2538(21)01056.
    >> Share

  77. KUME S
    Ketone bodies: back to a place in the sun.
    Kidney Int. 2021;100:976-978.
    >> Share

    October 2021
  78. MOLLER-HACKBARTH K, Dabaghie D, Charrin E, Zambrano S, et al
    Retinoic acid receptor responder1 promotes development of glomerular diseases via the Nuclear Factor-kappaB signaling pathway.
    Kidney Int. 2021;100:809-823.
    >> Share

    September 2021
  79. HEERSPINK HJ, Cherney D, Postmus D, Stefansson BV, et al
    A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
    Kidney Int. 2021 Sep 21. pii: S0085-2538(21)00865.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016